PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine

Summary

The purposes of this study is to evaluate and compare the safety, reactogenicity, and tolerability of the PA83-FhCMB vaccine candidate delivered at 4 dose levels with Alhydrogel

Timeline

Start

2014-08

Primary completion

2015-05

Completion

2015-05

Publications

• Paolino KM, Regules JA, Moon JE, Ruck RC, Bennett JW, Remich SA, Mills KT, Lin L, Washington CN, Fornillos GA, Lindsey CY, O'Brien KA, Shi M, Mark Jones R, Green BJ, Tottey S, Chichester JA, Streatfield SJ, Yusibov V. Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults. Vaccine. 2022 Mar 15;40(12):1864-1871. doi: 10.1016/j.vaccine.2022.01.047. Epub 2022 Feb 10.

Drugs

Indications